Anebulo Pharmaceuticals, Inc. (ANEB)
Anebulo Pharmaceuticals, Inc.
1017 Ranch Road 620 South
Suite 107
Lakeway, TX 78734
United States
(512) 598-0931
https://www.anebulo.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 2
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Joseph F. Lawler M.D., Ph.D. | Founder & Chairman | 11k | N/D | 1972 |
| Dr. Kenneth C. Cundy Ph.D. | Chief Scientific Officer | 425.15k | N/D | 1959 |
| Mr. Richard Anthony Cunningham | CEO & Director | N/D | N/D | 1971 |
| Mr. Daniel V. George | Principal Accounting Officer, Acting CFO & Secretary | N/D | N/D | 1970 |
| Mr. Scott L. Anderson | Head of Investor Relations & Public Affairs | N/D | N/D | N/D |
Descripción
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.
Gestión corporativa
La calificación ISS Governance QuickScore de Anebulo Pharmaceuticals, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
